Heidelberg Pharma AG

HPHA

Company Profile

  • Business description

    Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

  • Contact

    Gregor-Mendel-Street 22
    Ladenburg68526
    DEU

    T: +49 620310090

    E: [email protected]

    https://www.heidelberg-pharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 November 2025

    Employees

    109

Stocks News & Analysis

stocks

Is CSL undervalued after earnings season wobble?

The ASX's biggest healthcare name saw its shares fall after reporting first-half results.
stocks

After earnings is Apple stock a buy, sell or fairly valued?

Our thoughts on Apple's stock amid slowing iPhone sales but high services revenue.
stocks

Competition impacting ASX market darling

Shares tumble after results.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,799.6048.000.55%
CAC 408,028.9022.680.28%
DAX 4022,037.83126.090.58%
Dow JONES (US)44,593.65123.240.28%
FTSE 1008,777.399.590.11%
HKSE21,812.89518.032.43%
NASDAQ19,643.8670.41-0.36%
Nikkei 22538,963.70162.530.42%
NZX 50 Index12,913.953.50-0.03%
S&P 5006,068.502.060.03%
S&P/ASX 2008,535.3051.300.60%
SSE Composite Index3,346.3928.330.85%

Market Movers